摘要
目的探讨肺癌诊断中,肿瘤标志物检测的临床价值。方法采用回顾性分析的形式对我院2012年11月至2017年11月收治的26例肺癌患者以及25例肺部良性病症患者予以临床研究,采用ELISA法对NSE指标、Cy-fra21-1、TSGF、CA125、CA15-3、CA19-9以及CEA指标进行观察和测定。结果癌症组7种肿瘤标志物水平均高于良性病症组,组间对比差异性显著(P<0.05);在小细胞肺癌中,NSE为高表达,7种肿瘤标志物联合检测的灵敏度以及准确度分别为92.3%、91.0%,均优于单项检测。结论肿瘤标志物联合测定能够提升肺癌诊断的灵敏度以及准确度,合理对肺癌鉴别。
Objective To investigate the clinical value of tumor marker detection in the diagnosis of lung cancer.Methods A retrospective analysis was performed on 26 patients with lung cancer who were admitted to our hospital from November 2012 to November 2017 and 25 patients with benign pulmonary diseases. The NSE index and Cyfra21-1 were used by ELISA. TSGF, CA125, CA15-3, CA19-9 and CEA indicators were observed and measured. Results The levels of 7 tumor markers in the cancer group were higher than those in the benign group. The difference between the groups was significant(P< 0.05). In small cell lung cancer, NSE was highly expressed, and the sensitivity and accuracy of the combined detection of 7 tumor markers were accurate. The degrees were 92.3% and 91.0%, respectively,which were better than single test. Conclusion The combined determination of tumor markers can improve the sensitivity and accuracy of lung cancer diagnosis and rationalize the identification of lung cancer.
引文
[1]安仕刚.多项血清肿瘤标志物联合检测在肺癌诊断中的应用价值[J].国际检验医学杂志,2015(13):1844-1845,1848.
[2]李林,王迪进,万轲,等.CEA、CA125等肿瘤标志物联合检测在肺癌诊断中的价值[J].实用癌症杂志,2015(12):1789-1792.
[3]陈一超,辇伟奇,冉静,等.肿瘤标志物联合检测对肺癌诊断、病理分型和临床分期的临床价值[J].国际检验医学杂志,2018,39(1):32-37.